Journal
JOURNAL OF CELL COMMUNICATION AND SIGNALING
Volume 3, Issue 2, Pages 89-94Publisher
SPRINGER
DOI: 10.1007/s12079-009-0037-7
Keywords
CCN2; CTGF; Fibrosis; Biomarker
Categories
Funding
- Canadian Institute of Health Research
- Canadian Foundation for Innovation
- Ontario Thoracic Society
- Scleroderma Society
- Reynaud's and Scleroderma Association
- Arthritis Research Campaign
- Early Researcher Award
Ask authors/readers for more resources
The CCN (cyr61, ctgf, nov) family of modular proteins regulate diverse biological affects including cell adhesion, matrix production, tissue remodelling, proliferation and differentiation. Recent targeted gene disruption studies have demonstrated the CCN family to be developmentally essential for chondrogenesis, osteogenesis and angiogenesis. CCN2 is induced by agents such as angiotensin II, endothelin-1, glucocorticoids, HGF, TGF beta, and VEGF, and by hypoxia and biomechanical and shear stress. Dysregulated expression of CCN2 has also been widely documented in many fibroproliferative diseases. This mini-review will focus on CCN2, and the recent progress in understanding CCN2 gene regulation in health and disease. That CCN2 should be considered a novel and informative surrogate clinical bio-marker for fibroproliferative disease is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available